Boehringer Ingelheim Announces Pivotal Phase III Data Of Flibanserin In Pre-Menopausal Women With Hypoactive Sexual Desire Disorder

Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin is an investigational compound being developed by Boehringer Ingelheim for the treatment of HSDD in pre-menopausal women.

Source: Boehringer Ingelheim Announces Pivotal Phase III Data Of Flibanserin In Pre-Menopausal Women With Hypoactive Sexual Desire Disorder